Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 6:57 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1273–1296 of 2,277 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Melanoma Clear all
Recruiting No phase listed Observational

The Gut Microbiome and Immune Checkpoint Inhibitor Therapy in Solid Tumors

NCT05037825
View directory record Official record
Conditions
Non-Small-Cell Lung Carcinoma, Malignant Melanoma, Renal Cell Carcinoma, Triple-Negative Breast Cancer
Interventions
Checkpoint Inhibitor, Immune
Drug
Lead sponsor
VastBiome
Industry
Eligibility
18 Years and older
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
Elizabethtown, Kentucky
Source: ClinicalTrials.gov public record
Updated Apr 27, 2022 · Synced Oct 30, 2026, 6:57 PM EDT
Completed Phase 1Phase 2 Interventional

Vaccine Therapy in Treating Patients With Stage IV or Recurrent Melanoma

NCT00012064
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
therapeutic autologous dendritic cells
Biological
Lead sponsor
Lisata Therapeutics, Inc.
Industry
Eligibility
16 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2011
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Jan 29, 2014 · Synced Oct 30, 2026, 6:57 PM EDT
Not listed Phase 2 Interventional

A Study of Transgenic Lymphocyte Immunization (TLI) Against Telomerase in Subjects With Stage III Melanoma

NCT00925314
View directory record Official record
Conditions
Stage IIIB Skin Melanoma, Stage IIIC Skin Melanoma
Interventions
CB-10-01 (Transgenic Lymphocyte Immunization)
Biological
Lead sponsor
Cosmo Bioscience
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
5
States / cities
Duarte, California • Los Angeles, California • San Diego, California + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2012 · Synced Oct 30, 2026, 6:57 PM EDT
Completed Phase 1 Interventional

⁸⁹Zr-Df-IAB22M2C PET/CT in Patients With Selected Solid Malignancies or Hodgkin's Lymphoma

NCT03107663
View directory record Official record
Conditions
Positron-Emission Tomography, Immunomodulation, Metastatic Solid Malignancies, Hodgkin Lymphoma
Interventions
⁸⁹Zr-Df-IAB22M2C Infusion
Drug
Lead sponsor
ImaginAb, Inc.
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
3
States / cities
Scottsdale, Arizona • New York, New York • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 18, 2018 · Synced Oct 30, 2026, 6:57 PM EDT
Completed Phase 1 Interventional Results available

Dendritic Cell Vaccination in Patients With Advanced Melanoma

NCT03092453
View directory record Official record
Conditions
Melanoma
Interventions
Mature dendritic cell (DC) vaccine, Cyclophosphamide 300mg/m^2, Pembrolizumab
Biological · Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 24, 2024 · Synced Oct 30, 2026, 6:57 PM EDT
Completed Phase 1 Interventional

Phase I Study of MLN8237 and Pazopanib in Patients With Solid Tumors

NCT01639911
View directory record Official record
Conditions
Malignant Neoplasm of Breast, CNS Malignancy, Malignant Neoplasm of Gastrointestinal Tract, Genitourinary Neoplasms Malignancy and Gender Unspecified, Head and Neck Neoplasms, Melanoma, Malignant Neoplasm of Thorax
Interventions
Alisertib, Pazopanib
Drug
Lead sponsor
University of Illinois Chicago
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 22, 2019 · Synced Oct 30, 2026, 6:57 PM EDT
Completed Phase 3 Interventional Results available

A Study of NKTR-214 Combined With Nivolumab vs Nivolumab Alone in Participants With Previously Untreated Inoperable or Metastatic Melanoma

NCT03635983
View directory record Official record
Conditions
Melanoma
Interventions
NKTR-214, Nivolumab
Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
12 Years and older
Enrollment
783 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
24
States / cities
Tucson, Arizona • La Jolla, California • Stanford, California + 20 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2025 · Synced Oct 30, 2026, 6:57 PM EDT
Completed No phase listed Observational

Long-term Data Collection for Subjects in MDX-010 Studies

NCT00928031
View directory record Official record
Conditions
Metastatic Melanoma
Interventions
Not listed
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
11
States / cities
Tuscon, Arizona • Long Beach, California • Los Angeles, California + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2010 · Synced Oct 30, 2026, 6:57 PM EDT
Terminated Phase 2 Interventional Results available

A Study of Glembatumumab Vedotin as Monotherapy or in Combination With Immunotherapies in Patients With Advanced Melanoma

NCT02302339
View directory record Official record
Conditions
Melanoma
Interventions
glembatumumab vedotin, glembatumumab vedotin and varlilumab, glembatumumab vedotin and PD-1 targeted checkpoint inhibitor (nivolumab OR pembrolizumab), glembatumumab vedotin and CDX-301
Drug
Lead sponsor
Celldex Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
14
States / cities
Los Angeles, California • San Francisco, California • Fort Myers, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 6, 2019 · Synced Oct 30, 2026, 6:57 PM EDT
Completed Phase 2 Interventional Results available

A Study of Vemurafenib in Previously Treated Patients With Metastatic Melanoma

NCT00949702
View directory record Official record
Conditions
Malignant Melanoma
Interventions
vemurafenib
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
12
States / cities
Los Angeles, California • Denver, Colorado • Tampa, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2017 · Synced Oct 30, 2026, 6:57 PM EDT
Terminated Not applicable Interventional

Early FDG PET in Melanoma

NCT02716077
View directory record Official record
Conditions
Clinical Stage III Nodal or Intransit Disease or Resectable Stage IV Melanoma
Interventions
FDG PET/CT imaging
Radiation
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 23, 2021 · Synced Oct 30, 2026, 6:57 PM EDT
Terminated Phase 1 Interventional

Modified Virus VSV-IFNbetaTYRP1 in Treating Patients With Stage III-IV Melanoma

NCT03865212
View directory record Official record
Conditions
Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Choroid Melanoma, Metastatic Melanoma, Metastatic Mucosal Melanoma, Metastatic Uveal Melanoma, Pathologic Stage III Cutaneous Melanoma AJCC v8, Pathologic Stage IIIA Cutaneous Melanoma AJCC v8, Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8, Pathologic Stage IV Cutaneous Melanoma AJCC v8, Unresectable Melanoma
Interventions
Recombinant Vesicular Stomatitis Virus-expressing Interferon-beta and Tyrosinase Related Protein 1
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
2
States / cities
Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Oct 30, 2026, 6:57 PM EDT
Not listed Phase 1 Interventional

Abraxane and Temodar Plus Genasense in Advanced Melanoma

NCT00409383
View directory record Official record
Conditions
Melanoma
Interventions
Genasense® (oblimersen), Abraxane® (paclitaxel protein-bound particles for injectable suspension), Temodar® (temozolomide)
Drug
Lead sponsor
Genta Incorporated
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 7, 2011 · Synced Oct 30, 2026, 6:57 PM EDT
Active, not recruiting Phase 2 Interventional

A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 Melanoma

NCT06190951
View directory record Official record
Conditions
Melanoma
Interventions
cemiplimab, Fixed Dose Combination (FDC) cemiplimab+fianlimab, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
28
States / cities
La Jolla, California • Los Angeles, California • Newport Beach, California + 22 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Oct 30, 2026, 6:57 PM EDT
Completed Phase 1 Interventional

Gene Therapy and Ganciclovir in Treating Patients With Stage IV Melanoma

NCT00005057
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
adenovirus RSV-TK, ganciclovir
Biological · Drug
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
3
States / cities
Bethesda, Maryland • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 29, 2015 · Synced Oct 30, 2026, 6:57 PM EDT
Completed Phase 1 Interventional

Safety Study of MGA271 in Refractory Cancer

NCT01391143
View directory record Official record
Conditions
Prostate Cancer, Melanoma, Renal Cell Carcinoma, Triple-negative Breast Cancer, Head and Neck Cancer, Bladder Cancer, Non-small Cell Lung Cancer
Interventions
MGA271
Biological
Lead sponsor
MacroGenics
Industry
Eligibility
18 Years and older
Enrollment
179 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
12
States / cities
Los Angeles, California • New Haven, Connecticut • Tampa, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2022 · Synced Oct 30, 2026, 6:57 PM EDT
Terminated Phase 1 Interventional

A Phase 1a/1b Study of ACTM-838 in Patients With Advanced Solid Tumors

NCT06336148
View directory record Official record
Conditions
Solid Tumor
Interventions
ACTM-838
Drug
Lead sponsor
Actym Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
2
States / cities
Los Angeles, California • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 15, 2025 · Synced Oct 30, 2026, 6:57 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

War on Melanoma™ Public Health & Education Campaign

NCT04611568
View directory record Official record
Conditions
Melanoma
Interventions
Educational Intervention, Health Education, Media Campaign, Survey Administration
Other · Behavioral
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
12 Years and older
Enrollment
75,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2026
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 30, 2026, 6:57 PM EDT
Terminated Phase 1 Interventional

A Safety and MORAb-028 Dose Determination Study in Subjects With Metastatic Melanoma

NCT01212276
View directory record Official record
Conditions
Metastatic Melanoma, Malignant Metastatic Melanoma, Advanced Melanoma, Melanoma
Interventions
MORAb-028
Drug
Lead sponsor
Morphotek
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 16, 2014 · Synced Oct 30, 2026, 6:57 PM EDT
Completed Phase 1 Interventional

PET Imaging of Cancer Patients Using [18F]-SKI-249380, a Radiolabeled Dasatinib-Derivative

NCT01916135
View directory record Official record
Conditions
Carcinoma, Sarcoma, Myeloma, Lymphoma, Melanoma
Interventions
[18F]-SKI-249380, PET/CT scan, Blood draws
Radiation · Procedure · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
21 Years to 90 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 27, 2020 · Synced Oct 30, 2026, 6:57 PM EDT
Recruiting No phase listed Observational

Identification of Metabolic Phenotypes Associated With Melanoma Metastasis

NCT06400550
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
Not listed
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Oct 30, 2026, 6:57 PM EDT
Terminated Phase 1 Interventional

Safety Study of CALAA-01 to Treat Solid Tumor Cancers

NCT00689065
View directory record Official record
Conditions
Cancer, Solid Tumor
Interventions
CALAA-01
Drug
Lead sponsor
Calando Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
3
States / cities
Duarte, California • Los Angeles, California • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 1, 2013 · Synced Oct 30, 2026, 6:57 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Enhancing Skin Cancer Early Detection and Treatment in Primary Care

NCT05675709
View directory record Official record
Conditions
Cutaneous Melanoma
Interventions
Training and Education
Behavioral
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Dec 8, 2025 · Synced Oct 30, 2026, 6:57 PM EDT
Completed Phase 1 Interventional

A Phase 1B Clinical Trial of Trametinib Plus Digoxin in Patients With Unresectable or Metastatic BRAF Wild-type Melanoma

NCT02138292
View directory record Official record
Conditions
Melanoma
Interventions
Trametinib (2mg)/Digoxin (.25mg)
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
19 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 15, 2018 · Synced Oct 30, 2026, 6:57 PM EDT